It was tested in a phase 1 clinical trial for conditions such as cutaneous T-cell lymphoma (CTCL), chronic lymphocytic leukemia (CLL), and diffuse large B-cell lymphoma (DLBCL) which are known to be MYC-driven in a number of cases, and adult T-cell leukemia/lymphoma (ATLL) [67]. The gene discussed is MYC; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.